Chapter 8 - CLAIRE TESTIFIED UNDER OATH THAT HER OWN COMPANY FAILED HER DAUGHTER, AND WESTBROOK STOCK FELL NINE PERCENT BEFORE LUNCH
Claire Westbrook had testified before Congress before.
Infrastructure security.
Government procurement.
Cyber resilience.
She knew cameras.
She knew hostile questions.
She knew how senators performed outrage when television lights turned on.
This hearing was different.
Ellie sat behind her.
Not beside.
Logan next to Ellie.
Ben on other side.
The subject:
Medical Technology, Legacy Data, and Patient Consent in Commercial Innovation.
Westbrook Systems stock had already dropped four percent before hearing because investors feared liability.
Claire’s lawyers gave her safe language.
“Legacy subsidiary.”
“Historic governance limitations.”
“No evidence current leadership participated.”
All true.
Then Senator Amelia Grant asked:
“Ms. Westbrook, did an entity connected to your family’s company fail to protect medical records concerning your own daughter?”
Claire paused.
Counsel had prepared.
She ignored half.
“Yes.”
The room changed.
“Can you be more specific?”
“Records originally held within a predecessor research environment were copied during a poorly controlled archive migration.”
Another.
“My daughter’s medical data was among those records.”
“Did you authorize the later sale?”
“No.”
“Did your daughter?”
“No.”
“Did Westbrook Systems profit?”
“Not from Sonora’s sale.”
“Did Westbrook predecessor systems contribute to conditions that made the misuse possible?”
Claire looked at Ellie.
Then camera.
“Yes.”
Stock fell another two percent.
Somewhere investor-relations staff suffered.
Claire continued:
“We had weak prototype controls, weak archive segmentation, and inadequate deletion verification.”
“Did you know then?”
“No.”
“Does that matter?”
“Yes.”
Interesting.
“Why?”
“Intent matters for individual responsibility.”
Another.
“But lack of knowledge does not erase institutional failure.”
Good.
---
A senator hostile to large tech companies leaned.
“Isn’t this convenient? You admit broad corporate failure while denying personal responsibility.”
Claire did not flinch.
“I deny knowledge I did not have.”
Another.
“I accept responsibilities attached to role I do have.”
Precise.
“Your father built company.”
“Yes.”
“Your uncle participated in misconduct.”
“Yes.”
“Your daughter was harmed.”
“Yes.”
“Should families control medical-technology empires?”
Claire almost smiled.
“That is not a legal governance category.”
A few people laughed.
Then serious:
“I believe concentrated authority creates risk whether owner is family, founder, investor, physician, or government.”
That was new Claire.
“So what did you do?”
“Independent trustees.”
Another.
“Independent research governance.”
Another.
“Recusal from investigation involving my daughter.”
Another.
“External patient representation.”
Another.
“And I have proposed separating our remaining medical technology oversight from my direct board authority.”
Ellie’s head snapped up.
What?
Claire had not told.
Because it was Claire’s decision.
Interesting.
---
After hearing recess, Ellie cornered her.
“You’re stepping down?”
“From medical technology oversight committee.”
“When?”
“Board votes next month.”
“Why didn’t you tell?”
Claire smiled slightly.
“You told me to decide my own role.”
Damn.
Ellie laughed.
“Fair.”
“Do you think I’m running away?”
“No.”
“Good.”
“Do you?”
Claire thought.
“No.”
Another.
“I think founder-family authority has been too central too long.”
That mattered beyond case.
She would remain chair of Westbrook Systems overall for now.
But medical/health technology committee would be independently chaired.
Good.
No dramatic abdication.
Targeted governance.
---
Ellie testified after lunch.
Interpreter present.
CART captions.
She wore hearing devices for first hour then removed.
No one commented.
Good.
Senator Grant asked:
“Ms. Westbrook, what would you like law to require?”
Ellie did not say revenge.
She had a list.
“Provenance disclosure when medical datasets are sold.”
Another.
“Consent records preserved with version history.”
Another.
“Notice when legacy data are commercialized outside original institution.”
Another.
“Clear separation between de-identification and internal re-identification.”
Another.
“Adverse-event communication across multi-site trials.”
Another.
“And patient-accessible ways to revoke optional future data use when law allows.”
Technical.
Specific.
Useful.
Then senator asked:
“Would strict consent rules slow research?”
“Yes.”
That surprised.
“Sometimes.”
Another.
“So why support?”
“Because speed is not only value.”
Another.
“Trust is infrastructure.”
The phrase made Logan smile.
Emergency communications man.
Infrastructure.
Ellie continued:
“If people believe consent can be retroactively expanded whenever data become valuable, they stop participating.”
Another.
“That slows science too.”
Good.
---
A senator asked:
“Do you believe medical data should ever be used without specific consent for public-health research?”
Ellie said:
“Yes, under lawful frameworks with oversight.”
Again nuance.
“I am not arguing every dataset requires individualized permission for every statistical use.”
Another.
“My case involved identifiable records, a falsified consent document, and commercial use by people who knew provenance was disputed.”
Important.
No maximalist slogan.
---
Then one senator made mistake.
“Would you describe yourself as formerly deaf?”
Ellie paused.
The room froze.
She signed.
Interpreter voiced:
“No.”
Another.
“I am hard of hearing.”
Another.
“I grew up deaf and sign language remains part of my life.”
Another.
“Access to sound did not erase that history.”
The senator nodded awkwardly.
“My apologies.”
“Thank you.”
Move on.
No humiliation.
People can correct.
---
Stock ended day down nine percent.
Business media said Claire “sacrificed shareholder value for family optics.”
Others praised transparency.
Claire read neither.
Logan read and got angry.
She took his phone.
“Stop.”
“You’re being called reckless.”
“I have been called worse.”
“By me?”
“Often.”
Fair.
---
Westbrook board approved medical-tech governance changes 10–2.
Two directors resigned later over disclosure strategy.
Company recovered gradually.
Some old liabilities cost $68 million in legal, remediation, and data-notice programs.
Large.
Not fatal.
Claire told shareholders:
“Accountability is expense only if you believe error should be free.”
Good line.
Some hated.
Still.
---
The independent accessibility research center also changed.
Ellie resigned advisory board temporarily.
Why?
Because her current litigation/settlement relationship with Sonora could create conflicts with center considering Auralink technology.
Nobody asked.
She volunteered.
Claire said:
“You don’t have to.”
“I know.”
“That is why.”
Good.
Later she could return after conflicts expire.
---
Ben watched all.
He had become an infrastructure analyst, not public figure.
One night he told Ellie:
“Your family turns recusal into hobby.”
“Healthy.”
“Boring.”
“Responsible.”
“Still boring.”
Then he signed:
PROUD.
Ellie rolled eyes.
“Stop.”
“Why?”
“Everyone keeps proud-ing me.”
“Fine.”
He signed:
TOLERABLY IMPRESSED.
Better.
---
Then a surprise came from Dr. Priya Shah.
She had left Sonora.
Not fired.
Resigned.
She wanted to start independent engineering lab focused on user-controlled auditory devices.
She emailed Ellie:
I am not asking for your money.
Good opening.
I am asking whether you would review a design principle.
Attached concept:
A device with a physical hardware switch allowing user to disable all adaptive processing instantly.
No hidden auto-optimization.
No cloud requirement.
No remote updates without consent.
User-owned local settings.
Ellie stared.
That was exactly the kind of device she wished companies built.
Not because it “restored” anything.
Because it gave control.
She replied:
I’LL REVIEW. I AM NOT ENDORSING.
Priya:
PERFECT.
May you like
The next chapter of Ellie’s life began not with lawsuit.
With a prototype she was allowed to say no to before touching.
Related Stories
